Search research articles
Contact Us
Filters
Showing results (131-140 of 178) with videos related to
Page
of 18
Sort By:
Acta Neuropathologica Communications
|
January 4, 2022
Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study
Carine Jiguet-Jiglaire, Sebastien Boissonneau, Emilie Denicolai, et al.
Neuro-Oncology
|
February 24, 2016
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
Alba A Brandes, Antoine F Carpentier, Santosh Kesari, et al.
The Lancet. Oncology
|
November 8, 2015
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Hideho Okada, Michael Weller, Raymond Huang, et al.
Future Oncology (London, England)
|
June 26, 2018
The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?
Enrico Franceschi, Antonella Mura, Dario De Biase, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 11, 2009
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034
Martin J van den Bent, Alba A Brandes, Roy Rampling, et al.
The Lancet. Oncology
|
June 6, 2020
Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group
Craig Erker, Benita Tamrazi, Tina Y Poussaint, et al.
Neuro-Oncology
|
April 11, 2022
Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period
Marijke B Coomans, Linda Dirven, Neil Aaronson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2020
<i>PIK3CA</i> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2<sup>+</sup> Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
Valentina Guarneri, Maria Vittoria Dieci, Giancarlo Bisagni, et al.
The New England Journal of Medicine
|
March 11, 2005
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
Roger Stupp, Warren P Mason, Martin J van den Bent, et al.
World Neurosurgery
|
January 17, 2018
The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power
Enrico Franceschi, Alicia Tosoni, Santino Minichillo, et al.
Page
of 18
Search research articles
Search
Showing results (131-140 of 178) with videos related to
Sort By:
Page
of 18
Acta Neuropathologica Communications
|
January 4, 2022
Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study
Carine Jiguet-Jiglaire, Sebastien Boissonneau, Emilie Denicolai, et al.
Neuro-Oncology
|
February 24, 2016
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
Alba A Brandes, Antoine F Carpentier, Santosh Kesari, et al.
The Lancet. Oncology
|
November 8, 2015
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Hideho Okada, Michael Weller, Raymond Huang, et al.
Future Oncology (London, England)
|
June 26, 2018
The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?
Enrico Franceschi, Antonella Mura, Dario De Biase, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 11, 2009
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034
Martin J van den Bent, Alba A Brandes, Roy Rampling, et al.
The Lancet. Oncology
|
June 6, 2020
Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group
Craig Erker, Benita Tamrazi, Tina Y Poussaint, et al.
Neuro-Oncology
|
April 11, 2022
Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period
Marijke B Coomans, Linda Dirven, Neil Aaronson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2020
<i>PIK3CA</i> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2<sup>+</sup> Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
Valentina Guarneri, Maria Vittoria Dieci, Giancarlo Bisagni, et al.
The New England Journal of Medicine
|
March 11, 2005
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
Roger Stupp, Warren P Mason, Martin J van den Bent, et al.
World Neurosurgery
|
January 17, 2018
The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power
Enrico Franceschi, Alicia Tosoni, Santino Minichillo, et al.
Page
of 18